article thumbnail

China’s NMPA approves BeiGene’s Brukinsa to treat WM, CLL/ SLL

Pharmaceutical Technology

The small molecule Bruton’s tyrosine kinase (BTK) inhibitor Brukinsa has been specially designed for delivering sustained BTK protein inhibition by optimising bioavailability, half-life, and selectivity. In April this year, the regulator converted these conditional approvals to regular approvals for R/R WM and R/R CLL/SLL.

article thumbnail

Partners develop oral ketamine-based antidepressant for home use

Drug Discovery World

After making its scientific review of Ketamir-2, the DEA concluded that Ketamir-2 is not a controlled substance or listed chemical under the Controlled Substances Act (CSA) and its governing regulations.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Synthesis-to-Clinic®: integrating isotopic labeling and human ADME to reduce time to clinic

Pharmaceutical Technology

This is due to the fact that the current Good Manufacturing Practice (cGMP) standards required for human studies involve a significant investment in infrastructure and quality systems in order to efficiently comply with all national and international regulations. What makes Quotient Sciences’ approach to these study types unique?

article thumbnail

Potential treatment for anxiety and postpartum depression 

Drug Discovery World

1 The results also demonstrated exposure-dependent target engagement with γ-aminobutyric-acid type A (GABAA) receptors, which have been shown to regulate mood and other neurological conditions. Background Allopregnanolone is a natural neurosteroid with well-validated biological effects. Chief Medical Officer at PureTech.

article thumbnail

PharmaEngine, Inc. and Sentinel Oncology Limited Enter into an Exclusive Collaboration and License Agreement for SOL-578, a Chk1 inhibitor

The Pharma Data

SOL-578 is a best-in-class checkpoint kinase 1 (Chk1) inhibitor featuring high kinase selectivity and oral bioavailability which targets the DNA Damage Response (DDR) network. The company’s mission is to increase survival and improve outcomes for cancer patients with CNS tumors. ” said Yufang Hu , Ph.D., ” About SOL-578.

article thumbnail

Luye claims its first FDA approval, for bi-weekly schizophrenia drug

pharmaphorum

Rykindo has been approved for the treatment of schizophrenia and as monotherapy or adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder in adults by the US regulator.

article thumbnail

PROTACs show promise for cancer treatment

Pharmaceutical Technology

They provide a higher ability to regulate protein levels and can affect the non-enzymatic function of the protein while also providing an alternative to targeting drug-resistant proteins for overcoming tumour drug resistance. PROTACs are a type of heterobifunctional degrader that offers multiple advantages over traditional small molecules.

Protein 130